mTOR Inhibitors
| Cat. No. | Product Name / Activity |
|---|---|
| 7840 | AZD 8055 |
| Highly potent and selective mTOR inhibitor | |
| 6791 | BC-LI-0186 |
| Inhibits mTORC1 activity; leucyl-tRNA synthase (TRS)/Ras-related GTP-binding protein D (RagD) interaction inhibitor | |
| 6188 | Everolimus |
| mTOR inhibitor; Immunosuppressant | |
| 3725 | KU 0063794 |
| Selective mTOR inhibitor | |
| 4079 | Niclosamide |
| STAT3 inhibitor; also inhibits mTORC1 signaling | |
| 6792 | Omipalisib |
| High affinity mTOR inhibitor; also highly potent PI 3-kinase and potent DNA-PK inhibitor | |
| 2930 | PI 103 hydrochloride |
| Inhibitor of mTOR, PI 3-kinase and DNA-PK | |
| 4257 | PP 242 |
| Dual mTORC1/mTORC2 inhibitor | |
| 1292 | Rapamycin |
| mTOR inhibitor; immunosuppressant | |
| 5264 | Temsirolimus |
| mTOR inhibitor; antitumor | |
| 4247 | Torin 1 |
| Potent and selective mTOR inhibitor | |
| 4248 | Torin 2 |
| Potent and selective mTOR inhibitor | |
| 4282 | WYE 687 dihydrochloride |
| Potent and selective mTOR inhibitor |
Cancer Metabolism Product Guide
Our product guide reviews some of the main areas in cancer metabolism research and highlights products that can be used to explore metabolic pathways.
Request copyRequest PDFCancer Metabolism Life Science Poster
Taken from the Cancer Product Guide Edition 3
Our Cancer Metabolism poster summarizes the main metabolic pathways in cancer cells, and highlights potential targets for cancer therapeutics.
Request copyDownload PDF